Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 14, 2014 - Issue 12
Submit an article Journal homepage
220
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis

Omar Abdel-RahmanDepartment of Clinical Oncology, Faculty of Medicine, Ain shams University, Lotfy Elsayed street, Postal code: 11665, Cairo, EgyptCorrespondence[email protected]
&
Mona FouadDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Ain shams University, Cairo, Egypt
Pages 1529-1536 | Published online: 27 Aug 2014

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Lingaku Lee, Tetsuhide Ito & Robert T. Jensen. (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opinion on Pharmacotherapy 19:8, pages 909-928.
Read now
Omar Abdel-Rahman & Mona Fouad. (2015) Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Review of Anticancer Therapy 15:7, pages 847-858.
Read now
Omar Abdel-Rahman & Mona Fouad. (2015) Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. Expert Review of Anticancer Therapy 15:4, pages 477-486.
Read now

Articles from other publishers (8)

Zhiwei Wang, Xiao Yang, Jitao Wang, Shuai Wang, Xiaorong Mao, Mingxing Li, Yongzhao Zhao, Weidong Wang, Xiaolong Qi & Tongwei Wu. (2019) Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis. Journal of Cancer Research and Therapeutics 15:7, pages 1435.
Crossref
Amber Ilyas, Zehra Hashim, Iffat Saeed Channa & Shamshad Zarina. (2018) Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study. Hepatobiliary & Pancreatic Diseases International 17:3, pages 241-250.
Crossref
Hui Guo, Yan Zhong, Amanda L. Jackson, Leslie H. Clark, Josh Kilgore, Lu Zhang, Jianjun Han, Xiugui Sheng, Timothy P. Gilliam, Paola A. Gehrig, Chunxiao Zhou & Victoria L. Bae-Jump. (2016) Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer. Oncotarget 7:15, pages 20338-20356.
Crossref
Chun-Hui Cui, Shu-Xin Huang, Jia Qi, Hui-Juan Zhu, Zong-Hai Huang & Jin-Long Yu. (2015) Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis. Oncotarget 6:41, pages 44005-44018.
Crossref
Omar Abdel-Rahman, Hesham ElHalawani & Hoda Ahmed. (2015) Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis . Future Oncology 11:24, pages 3307-3319.
Crossref
Omar Abdel-Rahman, Hesham ElHalawani & Mona Fouad. (2015) Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncology 11:17, pages 2471-2484.
Crossref
Omar Abdel-Rahman & Mona Fouad. (2015) Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. Tumor Biology 36:2, pages 467-478.
Crossref
Calvin J. Meaney. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 471 490 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.